Research news items on the role of the p62 gene in ALS-FTD and the ALS-FTD-Q, a new screening tool for assessing behavioral disturbances in ALS
By Amy Madsen, originally posted at MDA/ALS NewsMagazine, September 26, 2012
The finding that mutations in the p62 gene can cause frontotemporal lobar degeneration, added to an earlier finding that such [...]
The new program, which launched in May 2012, provides eligible patients with a 6-month supply of drug, free of charge to help ensure access to NUEDEXTA. Program participants may qualify for ongoing assistance subject to periodic verification of eligibility.
Studies to support the effectiveness of Nuedexta were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).